Free Communications - Vaccines 1 - Male vaccines

2:15 PM • FC 04-01 • Introduction: HPV in males: rationale for gender neutral vaccination > A. Anna GIULIANO 2:25 PM • FC 04-02 • Long-term effectiveness and immunogenicity of quadrivalent HPV vaccine in young men: 10-year end-of study analysis > S. Stephen Goldstone 2:35 PM • FC 04-03 • Efficacy, immunogenicity and safety of the quadrivalent HPV L1 Virus-Like Particle (VLP) vaccine in 16- to 26-year-old Japanese men > A. Alain Luxembourg 2:45 PM • FC 04-04 • Long-term follow-up study of immunogenicity and effectiveness of the 9-Valent HPV (9cHPV) vaccine in preadolescents and adolescents (9-15 y.o.) > E. Elmar Joura 2:55 PM • FC 04-05 • Comparison of immunogenicty of 2-dose and 3-dose regimens of 9-valent HPV vaccine (3 year LTFU) > J. Jacob BORNSTEIN 3:05 PM • FC 04-06 • Human papillomavirus (HPV) seroprevalence and anogenital HPV detection among young heterosexual men > J. Joel PALEFSKY 3:15 PM • FC 04-07 • Human papillomavirus (HPV) seroprevalence and anogenital HPV detection among HIV-negative men who have sex with men (MSM) > S. Stephen Goldstone 3:25 PM • FC 04-08 • Identifying facilitators and barriers associated with expanding HPV vaccination programs to males > E. Edith Morais 3:35 PM • FC 04-09 • A systematic literature review of cost-effectiveness studies assessing the nonavalent HPV vaccine in a gender neutral population > S. Smita Kothari